MedPath

Shanghai Huaota Biopharmaceutical Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

13

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:11
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 1
11 (84.6%)
Phase 2
2 (15.4%)

A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants

Phase 1
Recruiting
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2025-05-31
Last Posted Date
2025-05-31
Lead Sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Target Recruit Count
52
Registration Number
NCT06999083
Locations
🇳🇿

New Zealand Clinical Research , Grafton, Auckland, 3 Ferncroft Street,, Auckland, Grafton, New Zealand

A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors

Phase 1
Conditions
Solid Tumors
Interventions
Drug: HB0052 Injection
First Posted Date
2025-05-28
Last Posted Date
2025-05-28
Lead Sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Target Recruit Count
30
Registration Number
NCT06992687
Locations
🇨🇳

Peking University Cancer Hospital, Peking, China

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

Phase 1
Recruiting
Conditions
Hidradenitis Suppurativa
Interventions
First Posted Date
2025-03-26
Last Posted Date
2025-06-17
Lead Sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Target Recruit Count
15
Registration Number
NCT06895499
Locations
🇨🇳

Dermatology Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China

A Study to Evaluate HB0034 in Healthy Chinese Adult Participants

Phase 1
Recruiting
Conditions
Healthy
Interventions
Drug: HB0034 matching placebo
First Posted Date
2024-12-04
Last Posted Date
2025-01-20
Lead Sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Target Recruit Count
60
Registration Number
NCT06716151
Locations
🇨🇳

Central Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China

A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants

Phase 1
Recruiting
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2024-09-25
Last Posted Date
2025-01-03
Lead Sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Target Recruit Count
46
Registration Number
NCT06612970
Locations
🇳🇿

New Zealand Clinical Research, Christchurch, New Zealand

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.